Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.35)
# 304
Out of 5,179 analysts
87
Total ratings
55.7%
Success rate
16.79%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Initiates: Buy | $13 | $5.75 | +126.09% | 1 | Mar 19, 2026 | |
| SEPN Septerna | Maintains: Buy | $34 → $35 | $23.87 | +46.63% | 2 | Mar 11, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $42.60 | +29.11% | 6 | Mar 4, 2026 | |
| BIIB Biogen | Maintains: Hold | $190 → $193 | $183.84 | +4.98% | 6 | Feb 9, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $62.50 | +47.20% | 5 | Feb 3, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $98.97 | +11.14% | 4 | Jan 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $78.16 | +48.41% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $52.92 | +5.82% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $510.68 | +25.32% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $90.30 | +2.99% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $13.05 | +14.94% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $28.50 | +75.44% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $737.71 | +10.07% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $10.10 | +8.91% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $10.61 | +135.63% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $878.24 | +18.19% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $209.40 | +3.63% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $27.04 | +18.34% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $30.84 | +62.13% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.32 | +3,990.91% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.04 | +197.62% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $14.76 | +143.90% | 1 | Jul 31, 2024 |
Inventiva
Mar 19, 2026
Initiates: Buy
Price Target: $13
Current: $5.75
Upside: +126.09%
Septerna
Mar 11, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $23.87
Upside: +46.63%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $42.60
Upside: +29.11%
Biogen
Feb 9, 2026
Maintains: Hold
Price Target: $190 → $193
Current: $183.84
Upside: +4.98%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $62.50
Upside: +47.20%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $98.97
Upside: +11.14%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $78.16
Upside: +48.41%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $52.92
Upside: +5.82%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $510.68
Upside: +25.32%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $90.30
Upside: +2.99%
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $13.05
Upside: +14.94%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $28.50
Upside: +75.44%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $737.71
Upside: +10.07%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $10.10
Upside: +8.91%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $10.61
Upside: +135.63%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $878.24
Upside: +18.19%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $209.40
Upside: +3.63%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $27.04
Upside: +18.34%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $30.84
Upside: +62.13%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.32
Upside: +3,990.91%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.04
Upside: +197.62%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $14.76
Upside: +143.90%